These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29368144)

  • 21. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
    J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
    Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
    Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
    Wu XY; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
    Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
    Dong S; Zhao N; Deng W; Sun HW; Niu FY; Yang JJ; Zhong WZ; Li F; Yan HH; Xu CR; Zhang QY; Yang XN; Liao RQ; Nie Q; Wu YL
    World J Surg Oncol; 2017 Jan; 15(1):12. PubMed ID: 28069039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
    Rounds A; Kolesar J
    Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Taniguchi Y; Tamiya A; Isa SI; Nakahama K; Okishio K; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Oct; 37(10):5857-5862. PubMed ID: 28982912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.